Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

Por um escritor misterioso

Last updated 06 abril 2025

Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study - eClinicalMedicine

Immunogenicity of SARS-CoV-2 vaccines in patients with cancer: Trends in Molecular Medicine

Pathogens, Free Full-Text

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study - The Lancet Haematology

Immunogenicity of two doses of BNT162b2 and mRNA‐1273 vaccines for solid cancer patients on treatment with or without a previous SARS‐CoV‐2 infection - La Verde - 2023 - International Journal of Cancer

Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial

Frontiers COVID-19 vaccination in patients with cancer: Opportunities and challenges

Recomendado para você